Cancer News and Research

Latest Cancer News and Research

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.

28 Jan 2013

Research into anesthesia neurotoxicity in the developing brain

Several studies have found evidence that children who undergo repeated surgical operations with general anesthesia before the age of 4 may be at an increased risk for learning disabilities.

28 Jan 2013

Certain forms of abuse negatively influence women cancer patients' quality of life

A new study by University of Kentucky researchers shows evidence that certain forms of abuse negatively influence women cancer patients' quality of life.

28 Jan 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

Less invasive treatment can provide superior survival to mastectomy in early stage breast cancer

Patients with early stage breast cancer who are treated with lumpectomy plus radiation have a better chance of survival compared with those who undergo mastectomy, according to Duke Medicine research.

28 Jan 2013

Qigong reduces depressive symptoms and improves QOL in women with breast cancer

Researchers from The University of Texas MD Anderson Cancer Center have found qigong, an ancient mind-body practice, reduces depressive symptoms and improves quality of life in women undergoing radiotherapy for breast cancer.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Telomerase gene mutation immortalizes deadly skin cancer

About ten percent of all cases of malignant melanoma are familial cases. The genome of affected families tells scientists a lot about how the disease develops. Prof. Dr. Rajiv Kumar of the German Cancer Research Center together with Prof. Dr. Dirk Schadendorf from Essen University Hospital studied a family where 14 family members were affected by malignant melanoma.

28 Jan 2013

Study shows how GATA3 protein acts downstream biochemically to prevent breast cancer metastasis

The spread of breast cancer to distant organs within the body, an event that often leads to death, appears in many cases to involve the loss of a key protein, according to UC San Francisco researchers, whose new discoveries point to possible targets for therapy.

28 Jan 2013

Research roundup: Does higher Rx drug spending lower Medicare costs?; Price transparency doesn't affect radiological decisions

Researchers aimed to find a relationship between geographic variation in Medicare Part D spending and medication-taking behavior among patients with diabetes or heart failure.

28 Jan 2013

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Seattle Genetics, Inc. today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA.

28 Jan 2013

Behavioral stress accelerates prostate cancer development in mice

Prostate cancer patients have increased levels of stress and anxiety; however, several recent studies have found that men who take drugs that interfere with the stress hormone adrenaline have a lower incidence of prostate cancer.

28 Jan 2013

Reducing the level of mutant p53 gene increases susceptibility to cancer treatment

Scientists from the National Cancer Centre Singapore (NCCS) have discovered the workings of the gene that has been hindering treatment response in cancer patients. This discovery was made after 5 years of studying the mutant form of the p53 gene, the major tumor suppressor in humans, which is generally found mutated in over 50% of all type of human cancers.

27 Jan 2013

Cancer News and Research

Latest Cancer News and Research

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

UMDNJ-School of Osteopathic Medicine to develop blood test that can diagnose MCI

Research into anesthesia neurotoxicity in the developing brain

Certain forms of abuse negatively influence women cancer patients' quality of life

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Less invasive treatment can provide superior survival to mastectomy in early stage breast cancer

Qigong reduces depressive symptoms and improves QOL in women with breast cancer

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Telomerase gene mutation immortalizes deadly skin cancer

Study shows how GATA3 protein acts downstream biochemically to prevent breast cancer metastasis

Research roundup: Does higher Rx drug spending lower Medicare costs?; Price transparency doesn't affect radiological decisions

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Behavioral stress accelerates prostate cancer development in mice

Reducing the level of mutant p53 gene increases susceptibility to cancer treatment

New research on flavonoids and nutritional health in older adults from JONGG

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Undetected comorbidities linked to increased mortality in schizophrenia

Periodontal health influences stem cell transplant success

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in